Fractyl Health (GUTS) versus Its Competitors Head-To-Head Review

Fractyl Health (NASDAQ:GUTS) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare Fractyl Health to related companies based on the strength of its institutional ownership, dividends, profitability, risk, earnings, analyst recommendations and valuation.

Institutional and Insider Ownership

40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 8.4% of Fractyl Health shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Fractyl Health and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-867.40%	-83.57%
Fractyl Health Competitors	-300.62%	-179.55%	-22.71%

Volatility and Risk

Fractyl Health has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500. Comparatively, Fractyl Health’s peers have a beta of 2.58, indicating that their average share price is 158% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Fractyl Health and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1	1	3	0	2.40
Fractyl Health Competitors	4295	10588	18373	832	2.46

Fractyl Health presently has a consensus target price of $50.25, indicating a potential upside of 5,461.09%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.55%. Given Fractyl Health’s higher probable upside, equities analysts plainly believe Fractyl Health is more favorable than its peers.

Valuation & Earnings

This table compares Fractyl Health and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Fractyl Health	$90,000.00	-$140.95 million	-0.09
Fractyl Health Competitors	$1.87 billion	$136.27 million	5.88

Fractyl Health’s peers have higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Fractyl Health peers beat Fractyl Health on 8 of the 12 factors compared.

About Fractyl Health

Fractyl Health is a clinical-stage therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company is based in Burlington, Massachusetts. Its lead program, Revita, is an investigational endoscopic procedure designed to resurface the lining of the duodenum, the first part of the small intestine. Fractyl is studying whether this approach can improve metabolic function and provide lasting benefits for people with type 2 diabetes. The company is also developing Rejuva, an experimental gene therapy platform intended to address obesity and related metabolic conditions.